Cinacalcet
- Generic Name
- Cinacalcet
- Brand Names
- Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22F3N
- CAS Number
- 226256-56-0
- Unique Ingredient Identifier
- UAZ6V7728S
- Background
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
- Indication
For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
- Associated Conditions
- Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Registration Number
- NCT00113958
Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 360
- Registration Number
- NCT00113945
A Research Study for Patients With End-Stage Renal Disease (ESRD)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 552
- Registration Number
- NCT00110890
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath